IDCU HomeInfectious Diseases A-CD-GH-LM-QR-ST-ZHealthcare SafetyVaccine Preventable DiseasesIDCU Health TopicsDisease ReportingRelated Rules & RegulationsImmunization BranchAbout IDCURelated DSHS Sites
  • Contact Us

    Infectious Disease Control Unit
    Mail Code: 1960
    PO BOX 149347 - Austin, TX 78714-9347
    1100 West 49th Street, Suite T801
    Austin, TX 78714

    Phone: (512) 776-7676
    Fax: (512) 776-7616



FAQs   Reporting   Resources

What is ehrlichiosis?
Ehrlichiosis was first described in dogs in 1935 and was not recognized as a human disease until the last half of the 20th century. Bacteria of the genus Ehrlichia cause a variety of diseases, both in humans and animals. Scientists continue to discover new species and to recognize different ways they cause disease. The bacteria are spread to humans through tick bites.

What are the symptoms of ehrlichiosis? What does ehrlichiosis cause?
Regardless of the species causing the infection, the symptoms and signs are similar. The diseases range anywhere from no symptoms, to an illness so mild that no medical attention is sought, to a severe, life-threatening condition. Most cause an abrupt onset of illness with fever, chills, headache, and malaise (a general ill feeling), usually beginning about 12 days after the tick bite. Patients may also experience confusion, nausea, vomiting, and joint pain. Some patients develop a rash involving the trunk and limbs.

Severely ill patients can develop abnormally low numbers of white blood cells, abnormally low numbers of platelets, and kidney failure.

Since 1986, two types of human ehrlichiosis have been identified in the U.S.: human monocytic ehrlichiosis (HME) and human granulocytic ehrlichiosis (HGE). The illnesses differ in the types of white blood cells the bacteria attack. In the U.S., HME has so far been concentrated in the southeastern and south central regions (including Texas). HGE has been found mainly in the upper Midwestern and northeastern states, but also in northern California.

Last updated April 3, 2019